Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola R+CHP) results in similar clinical outcomes than rituximab and dose adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R+DA-EPOCH) in patients with high-risk features diffuse large B-cell lymphoma (DLBCL): A single institution experience.

Rahul Thakur, Han Yu, Mariam Haji, Vaishali Deenadayalan, Vasanthan Kumarasamy, Ajinkya Buradkar, Jordan Scott, Grant Schofield, Dorothy Pan, Matthew Cortese, Francisco Hernandez-Ilizaliturri, Alex Niu

Blood (2025) 146 (Supplement 1): 3685.

https://doi.org/10.1182/blood-2025-3685

Published: 2025

Journal Articles

Inotuzumab Ozogamicin + Blinatumumab +/- Rituximab + Mini-Hcvd Shows Improved Tolerability with Similar Efficacy Compared to E1910 in Treatment of Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia in Older Adults

Jordan Scott, Samantha Poblete, Jared Vega, Amanda C. Przespolewski, James E Thompson, Elizabeth A. Griffiths, Pamela Jeannette Sung, Steven Green, Han Yu, Michael Shenal, Eugene Przespolewski, Eunice S. Wang, Jeffrey Baron

Blood (2023) 142 (Supplement 1): 5891.

https://doi.org/10.1182/blood-2023-181332

Published: 2023

Journal Articles

Impact of Anticonvulsant - Methotrexate Interactions on High Dose Methotrexate Clearance and Outcomes in Patients with Primary CNS Lymphoma

Ilana N Cypes, Angel Mier-Hicks, Jordan Scott, Adrienne Groman, Pallawi Torka, Catherine Gawronski, Eugene Przespolewski

Blood (2021) 138 (Supplement 1): 4358.

https://doi.org/10.1182/blood-2021-153967

Published: 2021